Breaking Business News: Crown Laboratories to Buy Revance Therapeutics in $924 Million Merger Deal
The Dermatology Digest
AUGUST 12, 2024
“Revance has an impressive track record in developing innovative aesthetics offerings that will complement Crown’s innovative line of skincare products. Crown shares our commitment to innovation and scale and will help us accelerate our growth. ” Mark J.
Let's personalize your content